These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 26372098)

  • 1. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
    Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.
    Cannon NA; Meyer J; Iyengar P; Ahn C; Westover KD; Choy H; Timmerman R
    J Thorac Oncol; 2015 Feb; 10(2):280-5. PubMed ID: 25299234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
    Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non-small cell lung cancer undergoing stereotactic body radiotherapy.
    Fang F; Jia Z; Xie H; Cao Y; Zhu X; Yang XY; Guo X; Zhang H
    Clin Respir J; 2024 May; 18(5):e13749. PubMed ID: 38685745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy.
    Shaverdian N; Veruttipong D; Wang J; Kupelian P; Steinberg M; Lee P
    J Thorac Oncol; 2016 Aug; 11(8):1319-1325. PubMed ID: 27234604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Location Matters: Stage I Non-Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes.
    Shaverdian N; Veruttipong D; Wang J; Kupelian P; Steinberg M; Lee P
    Clin Lung Cancer; 2017 Mar; 18(2):e137-e142. PubMed ID: 27908620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttreatment Immune Parameters Predict Cancer Control and Pneumonitis in Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
    Zheng Y; Shi A; Wang W; Yu H; Yu R; Li D; Xu B; Ma H; You J; Zhao D; Jiang L; Geng J; Zhu G
    Clin Lung Cancer; 2018 Jul; 19(4):e399-e404. PubMed ID: 29519614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?
    Unal D; Eroglu C; Kurtul N; Oguz A; Tasdemir A
    Asian Pac J Cancer Prev; 2013; 14(9):5237-42. PubMed ID: 24175807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy.
    Sebastian N; Wu T; Bazan J; Driscoll E; Willers H; Yegya-Raman N; Bond L; Dwivedi A; Mo X; Tan Y; Xu-Welliver M; Haglund K; Jabbour SK; Keane FK; Williams TM
    Radiother Oncol; 2019 May; 134():151-157. PubMed ID: 31005209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection.
    Hayes JT; David EA; Qi L; Chen AM; Daly ME
    Clin Lung Cancer; 2015 Sep; 16(5):379-84. PubMed ID: 25737143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer.
    Ueki N; Matsuo Y; Togashi Y; Kubo T; Shibuya K; Iizuka Y; Mizowaki T; Togashi K; Mishima M; Hiraoka M
    J Thorac Oncol; 2015 Jan; 10(1):116-25. PubMed ID: 25376512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NLR, MLR, and PLR are adverse prognostic variables for sleeve lobectomy within non-small cell lung cancer.
    Han R; Zhang F; Hong Q; Visar D; Zhan C; Zhao C; Wang F; Zhang S; Li F; Li J; Mu J
    Thorac Cancer; 2024 Aug; 15(24):1792-1804. PubMed ID: 39034535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic index score predicts outcome of patients with Stage I non-small cell lung cancer after stereotactic body radiation therapy.
    Shi S; Ye L; Zhao Q; Hu Y; Huang Y; Chen G; Zeng Z; He J
    Jpn J Clin Oncol; 2019 Apr; 49(4):367-372. PubMed ID: 30715411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
    Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
    Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.